Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $30.00 | Outperform | Oppenheimer |
| 11/12/2024 | $12.00 | Buy | UBS |
| 6/28/2024 | $23.00 → $6.00 | Buy → Neutral | Goldman |
| 5/2/2024 | $32.00 | Buy | H.C. Wainwright |
| 3/25/2024 | $26.00 | Outperform | Leerink Partners |
| 8/8/2023 | Outperform | TD Cowen | |
| 8/8/2023 | $67.00 | Overweight | Piper Sandler |
| 8/8/2023 | $33.00 | Buy | Goldman |
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
3 - Sagimet Biosciences Inc. (0001400118) (Issuer)
SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting fatty acid synthase (FASN) inhibitors will be given at the upcoming 9th Annual MASH-TAG Conference being held January 9-11, 2025 in Park City, Utah. The presentation will focus on the differentiated mechanism of action of the FASN inhibitor denifanstat and the observed anti-fibrotic effect in the Phase 2b FASCINATE-2 study in F2/F3 MASH. MASH-TAG 2025 Presentation Details: Title:FASN InhibitorsPresen
SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 10 a.m. EST in New York City, New York. A webcast of the presentation will be available in the Investors & Media section of Sagimet's website at www.sagimet.com, with an archived replay available for 90 days following the live event. About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developin
Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients Both artificial intelligence (AI) and conventional pathology demonstrated denifanstat's strong anti-fibrotic activity FASN inhibitor treatment reduced atherosclerosis development in mouse model of dyslipidemia and MASH SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
10-Q - Sagimet Biosciences Inc. (0001400118) (Filer)
Oppenheimer initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $30.00
UBS initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $12.00
Goldman downgraded Sagimet Biosciences from Buy to Neutral and set a new price target of $6.00 from $23.00 previously
SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)
SC 13G - Sagimet Biosciences Inc. (0001400118) (Subject)
SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)
SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202
SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET. The event will feature Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, who was the Principal Investigator on the Phase 2b FASCINATE-2 clinical trial and serves as a scientific advi